Element Biosciences raises Series B financing
Gunderson Dettmer client and DNA sequencing technology company Element Biosciences has raised $80 million in a Series B financing. The funding round included investors Fidelity Management & Research Company, JS Capital, Foresite Capital and Venrock.
In the announcement of the funding Element Biosciences CEO and co-founder Molly He said, “Element’s vision is to create disruption in each of the basic elements that comprise a sequencing platform, such as surface chemistry, sequencing chemistry, detection, and data analysis. With a combination of Element’s proprietary technologies and the latest developments in these respective areas, we have developed a flexible, modular, and high-performing sequencing platform.”